Everything below concerns prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-17. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
This aspect of the book has become known to a wider public through Kermani's repeated tributes to Father Paolo and his order, for example in Kermani's highly acclaimed German Publishers Association Peace Prize speech.
== History == The professional association began as the American Society for Medical Technology (ASMT) and is now known as the American Society for Clinical Laboratory Science (ASCLS). ASMT was organized in 1933 and incorporated in 1936. Early on, members were required to be certified by the Board of Registry (now the Board of Certification) of the American Society of Clinical Pathologists (ASCP) to ensure credibility of the society. During the 1930s, ASMT activities included the inception of a journal, the establishment of a Constitution and Bylaws, the emergence of state charters, and educating the public about the profession. In 1947, ASMT held its first independent convention, compared to earlier national meetings which were held in conjunction with physician groups. During the 1950s, the ASMT Research Fund was established to advance research efforts. In 1962, qualifications for the clinical laboratory scientist (medical technologist) changed to include a baccalaureate degree and a new category of laboratory technician emerged. Also in the 1960s, ASMT joined the International Association of Medical Laboratory Technologists. In the 1970s ASMT grew considerably in numbers (over 30,000 in 1976). The Professional Acknowledgment for Continuing Education (PACE) Program for validating and documenting continuing education was introduced, and the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS) was formed as an independent accreditation agency.
=== Early puberty === CPA is used as an antiandrogen and antiestrogen to treat precocious puberty in boys and girls. However, it is not fully satisfactory for this indication because it is not able to completely suppress puberty. It does not suppress skeletal maturation enough to avoid a reduction in height at adulthood. For this reason, CPA has mostly been superseded by GnRH agonists in the treatment of precocious puberty. CPA is not satisfactory for gonadotropin-independent precocious puberty. CPA has been used at dosages of 50 to 300 mg/m2 to treat precocious puberty.
It is produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972, from samples of S. hygroscopicus found on Easter Island. The compound was originally named rapamycin after the native name of the island, Rapa Nui. Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR. It was approved by the US Food and Drug Administration (FDA) in 1999. Hyftor (sirolimus gel) was authorized for topical treatment of facial angiofibroma in the European Union in May 2023.
== Dehydration methods == People have practiced food preservation since ancient times. Many folktales describe ways of preserving foods in one way or another according to local and cultural traditions. Dehydration methods help to prevent food from spoilage and to maintain it for a longer period of time while keeping it suitable for consumption. Reducing the amount of water in fruits helps prevent growth of bacteria, yeast or fungi. There are several processes that can be used in the production of dried fruit, each of which affects its appearance, rehydration properties, and nutrients differently. These drying processes include sun drying, tray (air) drying, freeze drying, and vacuum microwave drying. Each process has advantages and disadvantages.
Sources: en.wikipedia.org
== Namibian independence == The initial terms of the Geneva Protocol and Security Council Resolution 435 provided the foundation from which a political settlement in South West Africa could proceed: holding of elections for a constitutional assembly, confinement of both PLAN and the SADF to their respective bases, the subsequent phased withdrawal of all but 1,500 SADF troops, demobilisation of all paramilitary forces that belonged to neither the SADF nor to the police, and the return of refugees via designated entry points to participate in elections. Responsibility for implementing these terms rested with UNTAG, which would assist in the SADF withdrawal, monitor the borders, and supervise the demobilisation of paramilitary units.
== Similar approaches == The idea of using protein design to accomplish the same goals as DNA origami has surfaced as well. Researchers at the National Institute of Chemistry in Slovenia are working on using rational design of protein folding to create structures much like those seen with DNA origami. The main focus of current research in protein folding design is in the drug delivery field, using antibodies attached to proteins as a way to create a targeted vehicle.
== Career == Chen began her career at the Institute of Chemistry of Academia Sinica as assistant research fellow in 1999. She was the Director of the Institute of Chemistry from 2013 to 2019, and is currently a Distinguished Research Fellow. She is also an adjunct professor at National Taiwan University, National Chiayi University, National Taiwan Ocean University, and National Chung Hsing University. She conducts research in mass spectrometry-based bioinformatics, in relation to understanding diseases such as cancer. Since 2016, Chen has participated in the US Cancer Moonshot Initiative, providing proteogenomics expertise as representative of Academia Sinica. She is the project investigator for the Taiwan Cancer Moonshot Project, which analyzes multiomic data related to gastric cancer. She participates in the Chromosome-centric Human Proteome Project, and is the group lead of chromosome 4. Chen served as president for the Human Proteome Organization (2021-2022), the Taiwan Proteomics Society, and the Taiwan Society for Mass Spectrometry (2012-2015). She has been a council member of the Asia Oceania Human Proteome Organization since 2019. She current serves as executive director of the Taiwan Proteomics Society (2021-2023), and the Taiwan Society for Mass Spectrometry. She served on editorial boards of European Journal of Mass Spectrometry, Journal of Proteome Research, and Frontiers in Analytical Chemistry, and currently serves on the Executive Advisory Board of Proteomics.
Erik Johnson, the project lead, said that the Hunters are "big and impressive, but they can go anywhere the player can go", as the player can encounter them both indoors and outdoors. Ted Backman, a senior artist, said the Hunter can express emotions to show the player it is aggressive, hurt, or angry. Hunters are aggressive and they tend to operate in packs, but can also be found supporting other Combine troops. Later, they support Strider enemies, using their flechette guns to protect them. Hunters primarily attack the player by bracing themselves and firing bursts from their flechette cannon. Four flechettes can vaporize an ordinary human soldier. If they do not strike a living target, the flechettes charge up for several seconds and then explode, dealing minor damage to everything nearby. Hunters may also conduct a charging attack or strike with their legs if the player gets too close. Hunters are vulnerable to all weapons, but to compensate, are still quite resilient, making explosives and the pulse rifle's charged energy ball the most attractive options. Objects thrown with the gravity gun are also effective, especially if the player catches some of their flechettes with the object before hurling it. In outdoor environments, they can be run over with a vehicle.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.